FINWIRES · TerminalLIVE
FINWIRES

$GLSI

2 stories mentioning GLSIUpdated 1h ago

Every FINWIRES story that references GLSI, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday

Healthcare stocks were mixed pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.6%.Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) said a phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, failed to meet the primary efficacy endpoint. Shares of Astrazeneca were down more than 7% and Ionis Pharmaceuticals stock fell past 19% premarket.Greenwich LifeSciences (GLSI) shares were up more than 7% after the company said the European Medicines Agency cleared the use of commercially manufactured GP2 in a phase 3 trial evaluating GLSI-100 to prevent breast cancer recurrence in Europe.Natera (NTRA) said its Signatera molecular residual disease test received European Union In Vitro Diagnostic Regulation Class C certification for use across multiple solid tumor types. Shares of Natera were down more than 1% pre-bell.

$AZN$GLSI$IBB$IONS$NTRA$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.3%.Greenwich LifeSciences (GLSI) shares were up more than 5% after the company said the European Medicines Agency cleared the use of commercially manufactured GP2 in a phase 3 trial evaluating GLSI-100 to prevent breast cancer recurrence in Europe.

$GLSI

Track with the FINWIRES app suite